CA
NZ
UK
AU
IND
US
Adjusted net operating results were a loss of USD 4.4 million, compared with income of USD 17.4 million. The net loss from discontinued operations was USD 133 thousand, compared with USD 572 thousand, reflecting litigation and other costs related to the sale of JRG …
Net income was USD 4.3 million, compared with USD 2.5 million, andDiluted Earnings per Sharewere USD 0.75, compared with USD 0.45. For the six months, revenues were USD 122.5 million, compared with USD 120.3 million, andNet Incomewas USD 7.2 million in both periods.
Management fees were USD 1.2 billion. Excluding catch-up fees in all periods, management fees grew 16% year over year, and 19% over the first nine months of 2026.Assetsunder management that have not yet turned on and are not paying management fees ended the quarter …
Gross margin was 24.2%, compared with 19.3% a year earlier. It was affected by noncash expenses of 2.8 percentage points and benefited from one-time items of 5.7 percentage points, including approximately USD 11.1 million of IEEPA tariff refunds. Unfavorable foreign exchange reduced it by …
Adjusted EBITDA was USD 6 million, up 45% and the company's highest third quarter result to date.Cash Flowfrom operations was USD 7.6 million, which management tied to second half seasonality of cash generation.
The company stated that it experienced a significant reduction inDemandfor its products in the quarter, with sales declining across markets.
Net income attributable to Kemper Corporation was USD 52.4 million, or USD 0.89 per unrestricted common share, compared with a net loss attributable to Kemper Corporation of USD 21.0 million, or USD 0.34 per unrestricted common share, in the same period of 2025.
Chief Executive Officer Paul R. Gudonis said the results reflect execution on four success pillars: building recurring patient sources, expanding payer access, demonstratingOperating Leverageand investing in product development and clinical research.
Chief Executive Officer Silvio Napoli opened the call by presenting five facts as first evidence of progress, three months after laying out a framework built on three priorities and four Must-Win projects.
Net income was USD 5.6 million, compared with USD 5.8 million, andNet Incomeper diluted share was USD 0.43, compared with USD 0.46. Adjusted EBITDA was USD 29.6 million, compared with USD 20.8 million. For the nine months, total revenues were USD 161.1 million versus …
Please wait processing your request...